Slide 1: Phase 3 DIAMOND Trials Topline Results in DME
OCS-01 Phase 3 DIAMOND Trials Topline Results in DME May 29, 2026
Slide 2: Safe Harbor Statements
Safe Harbor Statements Cautionary note on forward-looking statements These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “i
Slide 3: Phase 3 DIAMOND Program Topline Results Summary
Phase 3 DIAMOND Program Topline Results Summary DIAMOND-1 DIAMOND-2 Visual function: Primary endpoint not met • OCS-01: 1.2 letters • OCS-01: 4.6 letters Mean Change in BCVA from Baseline at Week 52 • Vehicle: 5.1 letters • Vehicle: 5.2 letters Retinal anatomy: Rapid and sustained reduction • OCS-01
Slide 4: Study Design and Patient Population
Study Design and Patient Population 4
Slide 5: OCS-01 Phase 3 DIAMOND Program in DME
OCS-01 | Phase 3 DIAMOND Program in DME Objective Endpoints Study Population Evaluate the safety and efficacy of OCS- Primary endpoint: • Age 18-85 years 01 vs vehicle for the treatment of DME in • Change in BCVA ETDRS letter score at • Confirmed diagnosis of DME two adequate and well-controlled glo
Slide 6: DIAMOND Patient Disposition
Diamond Patient Disposition ITT Population DIAMOND-1 DIAMOND-2 Screened Screened n=689 n=713 Screen failures Screen failures n=285 n=312 Randomized Randomized n=404 1 patient randomized, not dosed n=401 OCS-01 Vehicle OCS-01 Vehicle n=200 n=203 n=200 n=201 Discontinued study Discontinued study Disco
Slide 7: DIAMOND Baseline Demographics
Diamond Baseline Demographics ITT Population DIAMOND-1 DIAMOND-2 OCS-01 Vehicle OCS-01 Vehicle Parameter (N=200) (N=203) (N=200) (N=201) Age, mean years (SD) 63.5 (9.77) 64.2 (9.57) 65.0 (8.68) 64.7 (8.33) Sex, n (%) Male 120 (60.0) 111 (54.7) 113 (56.5) 108 (53.7) Female 80 (40.0) 92 (45.3) 87 (43.
Slide 8: Efficacy
Efficacy 8
Slide 9: Mean Change in CST, Baseline to Week 52: DIAMOND-1
Mean Change in CST, Baseline to Week 52 ITT Population Mean Change in CST Baseline to Week 52 DIAMOND-1 40 30 P <0.0001 P <0.0001 P <0.0001 P <0.0001 P <0.0001 P <0.0001 P =0.0013 P =0.0023 P =0.0396 P NS 20 8.9 10 0 -1.5 from baseline, µm (± SE) 0.5 LS mean change in CST -13.8 -12.2 -8.5 0 5.4 -18.
Slide 10: Mean Change in CST, Baseline to Week 52: DIAMOND-2
Mean Change in CST, Baseline to Week 52 ITT Population Mean Change in CST Baseline to Week 52 DIAMOND-2 40 30 P <0.0001 P <0.0001 P <0.0001 P <0.0001 P <0.0001 P =0.0002 P <0.0001 P <0.0001 P <0.0001 P=0.0016 20 5.1 5.4 10 from baseline, µm (± SE) LS mean change in CST 0 0 -7.1 -16.4 -8.3 -18.8 -10
Slide 11: Visual Function: Primary Endpoint Mean Change in BCVA at Week 52
Visual Function: Primary Endpoint Mean Change in BCVA from Baseline at Week 52 ITT Population Mean Change in BCVA Mean Change in BCVA from Baseline at Week 52 from Baseline at Week 52 DIAMOND-1 DIAMOND-2 8 8 P value NS P value NS LS mean change in BCVA ETDRS letters LS mean change in BCVA ETDRS lett
Slide 12: Visual Function: Key Secondary Endpoint ≥15-Letter Gain in BCVA
Visual Function: Key Secondary Endpoint ≥15-Letter Gain in BVCA at Week 52 ITT Population ≥15-Letter Gain from Baseline at Week 52 ≥15-Letter Gain from Baseline at Week 52 DIAMOND-1 DIAMOND-2 35 35 P value NS P value NS Patients with ≥15 ETDRS letter gain Patients with ≥15 ETDRS letter gain 30 30 25
Slide 13: Safety
Safety 13
Slide 14: Safety Summary
Safety Summary • OCS-01 was well tolerated, with no unexpected adverse events observed. • Overall safety profile was consistent with that of previous trials. • As expected, elevated IOP and cataracts were higher in the OCS-01 treated patients in line with chronic use of steroid in DME. 14
Slide 15: Summary
Summary 15
Slide 16: OCS-01 DIAMOND TLR Summary and Pipeline Prioritization
OCS-01 DIAMOND TLR Summary and Pipeline Prioritization • Despite showing a rapid, substantial and sustained reduction in retinal thickness in patients treated with OCS-01, primary (mean change in BCVA) and key secondary (≥15-letter gainers) endpoints for both trials were not met at Week 52. • Based
Slide 17: Q&A
culls Q&A